FDA Investigator Syed N Ali

Syed N Ali has inspections in 6 countries as of 18 Sep 2023. Syed N Ali has collaborated with a combined 1807 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
Last Inspection Date:
18 Sep 2023
Investigator Role:
FDA Investigator
Redica ID:
China, Czechia, Slovenia, India, Slovakia
Alberto A Viciedo, Albinus D'sa, PhD, Albinus M D Sa, Arsen Karapetyan, Atul J Agrawal, Azza Talaat, Bo Chi, PhD, Carl Lee, Carolina D Vasquez, Charanjeet Jassal, Charisse K Green, Charles M Edwards, Clinton J Lott, Concepcion Cruz, Jr, Cynthia J Lee, MS, Daniel J Roberts, Dennis Cantellops Paite, Dipesh K Shah, Donald L Lech, Dongping Dai, PhD, Dr. Chunchang Fang, Dr. Robert C Horan, MD, Dr. S Nar Ali, PhD, Erika V Butler, Farhana Khan, Felix Maldonado, Gayle S Lawson, George J Flynn, George Pyramides, Gwyn G Dickinson, Helen Verdel, Ivis Lnegron Torres, James P Mcreavey, Javier O Vega, Jawaid Hamid, Jeffery A Hangartner, Jeffrey P Raimondi, Joel D Hustedt, John A Gonzalez, John D White, John M Dietrick, Jonah S Ufferfilge, Jorge L Guadalupe, Jose R Hernandez, Justin A Boyd, Karen K Moksnes, Karen Takahashi, Karyn M Campbell, Katherine Szestypalow, Kent C Faul, Kevin A Gonzalez, Kham Phommachanh, Larry K Austin, Laurimer Kuilan Torres, Liqun Zhao, Maotang Zhou, PhD, Matthew B Casale, Meisha R Sampson, Michael A Charles, Michael A Taylor, Michael R Goga, Michael S Araneta, Michael Shanks, MS, Michele L Obert, Muralidhara B Gavini, PhD, Nasir Ali, PhD, Nicholas P Diorio, Nicole E Knowlton, Peter E Baker, Philip F Istafanos, DMV, MS, Pratik S Upadhyay, DDC, Regan T Harp, Regina T Brown, Richard L Rutherford, Robert C Henry, Robert D Tollefsen, Robert J Martin, Rochelle K Kimmel, Rochelle L Cross, Roger F Zabinski, Saied A Asbagh, Sangeeta M Khurana, PhD, Sarah E Mcmullen, Scott B Laufenberg, Scott T Ballard, Sharon K Thoma, PharmD, Shirley H Isbill, Steven D Kehoe, Steven P Donald, Susan F Laska, MS, Susan W Ting, Susanna E Ford, Analyst, Suzanne M Healy, Taichun Qin, PhD, Teresa I Navas, Thomas J Arista, Thomas S Savage, Tracey L Harris, Uduak M Inokon, Yvins Dezan, Zi Qiang Gu

Syed N Ali's Documents

Publish Date Document Type Title
March, 2001 EIR Southwest Synthetic Pharmaceutical Corporation Limited - EIR, 2001-05-11
November, 2000 FDA 483 Response Sun Pharmaceutical Industries Limited - Form 483R, 2000-11-28
June, 2000 EIR Spolana Sa - EIR, 2000-06-29
October, 2000 FDA 483 Response Sun Pharmaceutical Industries Limited - Form 483R, 2000-12-04
October, 2000 EIR Sun Pharmaceutical Industries Limited - EIR, 2000-10-27
May, 2002 EIR Yangzhou Pharmaceutical Ltd - EIR, 2002-06-19
October, 2000 FDA 483 Sun Pharmaceutical Industries Limited - Form 483, 2000-10-27
October, 2000 FDA 483 Sun Pharmaceutical Industries Limited - Form 483, 2000-10-20
October, 2000 EIR Sun Pharmaceutical Industries Limited - EIR, 2000-10-20
September, 2001 FDA 483 Response CIPLA LIMITED - Form 483R, 2001-10-10
March, 2001 FDA 483 Southwest Synthetic Pharmaceutical Corporation Limited - Form 483, 2001-03-09
November, 2000 EIR Sun Pharmaceutical Industries Limited - EIR, 2000-11-02
September, 2001 EIR CIPLA LIMITED - EIR, 2004-08-19
September, 2002 FDA 483 Hunan KYF Pharmaceutical. Co., Ltd - Form 483, 2002-09-05
June, 2000 FDA 483 Response Zentiva A.S. - Form 483R, 2000-07-11
May, 2002 FDA 483 Yangzhou Pharmaceutical Ltd - Form 483, 2002-05-23
May, 2002 FDA 483 Shandong Xinhua Pharmaceutical Co Ltd. First Plant - Form 483, 2002-05-30
May, 2002 FDA 483 Response Yangzhou Pharmaceutical Ltd - Form 483R, 2002-06-28
September, 2001 FDA 483 CIPLA LIMITED - Form 483, 2001-09-14
May, 2002 EIR Shandong Xinhua Pharmaceutical Co Ltd. First Plant - EIR, 2002-06-28
November, 2000 FDA 483 Sun Pharmaceutical Industries Limited - Form 483, 2000-11-02
June, 2000 EIR Zentiva A.S. - EIR, 2000-06-22
August, 2002 EIR Shandong Qilu King-phar Pharmaceutical Co., Ltd. - EIR, 2002-08-29
May, 2001 FDA 483 Jiangsu Hengrui Medicine Co., Ltd. - Form 483, 2001-05-25
June, 2000 FDA 483 Spolana Sa - Form 483, 2000-06-29

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles


Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more